@FiercePharma: Mallinckrodt Pharmaceuticals and Zogenix to End Co-Promotion Agreement. Release | Follow @FiercePharma
@TracyStaton: Most popular special report FiercePharma today: Top 10 Drug Patent Losses of 2014. Report | Follow @TracyStaton
@EricPFierce: Let us satisfy your app..etite for FiercePharma news. iOS folks here; Android here. | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: J&J's Imbruvica bests GSK's Arzerra in CLL trial, raising hopes for off-label sales. Story | Follow @CarlyHFierce
> South African drugmaker Adcock Ingram, up for sale, has once again delayed a shareholder vote on a $1.2 billion takeover offer from Chile's CFR Pharmaceuticals. Report
> Johnson & Johnson ($JNJ) submitted a citizen petition to the FDA, asking the agency to require biosimilar drugs to be named similarly to their reference products, but not identically. Report
> French health authorities approved GW Pharmaceuticals' cannabis-based drug, Sativex, to treat muscle spasms associated with multiple sclerosis. Report
> Some over-the-counter laxatives containing sodium phosphate can be dangerous if used too often, the FDA said. Report
> Amneal Pharmaceuticals tapped former Warner Chilcott SVP Rochelle Fuhrmann as its CFO. Report
@FierceMedDev: Avelas Biosciences closes $6.85M Series B for real-time cancer visualization tech. Release | Follow @FierceMedDev
@MichaelGFierce: Hot on FierceDrugDelivery this week: How a single nanoparticle delivers two drugs separately to kill cancer cells. Story | Follow @MichaelGFierce
@EmilyWFierce: FiercePharma has gone mobile! Check out the new app here. | Follow @EmilyWFierce
@MarkHFierce: Sorin knows: a local device development partner in China is good way to boost its market presence there. Story | Follow @MarkHFierce
> Medtronic's flunked trial throws its hypertension program into doubt. Story
> Facing a Dx sales slump, Quest taps Illumina, Life Tech and UCSF for R&D. More
> Covidien, NEA and Lightstone are backing a stealthy Irish med tech startup. News
> Lombard plots a U.S. IPO as aortic aneurysm device takes off. Article
Biotech News
@FierceBiotech: Intercept halts FLINT trial early after meeting endpoint in nonalcoholic steatohepatitis. Release | Follow @FierceBiotech
@JohnCFierce: Oh, man. Intercept up to $255 - or +250%. Market cap now just under $5B. | Follow @JohnCFierce
@DamianFierce: Zymeworks pockets $15M, woos Eli Lilly with its double-barreled antibodies. Story | Follow @DamianFierce
@EmilyMFierce: ICYMI: Embryonic-like stem cells created from frozen tissue of Alzheimer's patients. Story from FierceBiotech Research | Follow @EmilyMFierce
> One of biotech's top R&D chiefs makes the leap to the VC crowd at NEA. Story
> Biogen Idec forges a $320M gene editing deal aimed at curing inherited blood disorders. News
> Intercept shares dazzle after early success of PhIIb liver disease drug trial. More
> Pfizer outsources PhIII Bosulif study to upstart Avillion. Item
Pharma Manufacturing News
> McKesson's new offer appeases hedge fund on Celesio buyout. Story
> FDA names Sklamberg to oversee global regulatory issues. Item
> Roche's Genentech tells the FDA to expect a brief Tamiflu shortage. Article
> Patheon's deal for DSM would transform it into the 2nd largest CMO in the world. News
> Amgen facility has its 2nd explosion in 9 months. More
> Rumored Novartis, Merck asset swap has interesting manufacturing implications. Report
Vaccines News
> Astellas inks deal to create a portfolio of vaccine-focused biotechs. Story
> H1N1 deaths drive a surge in demand for flu vaccine. Report
> China gives hep B vaccine a clean bill of health but suspicions remain. News
> Study finds giving Prevnar and flu vaccine together raises risk of fever. More
> Students in California are still waiting for Novartis' Bexsero to arrive. Article
> Protein Sciences calls on Connecticut to buy its flu vaccine. Item
And Finally... Canada's health minister said a person died in Alberta this week of the H5N1 flu virus; officials called it an "isolated case." Report (sub. req.)